Exact Mass: 1074.471
Exact Mass Matches: 1074.471
Found 17 metabolites which its exact mass value is equals to given mass value 1074.471,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Mpomeovt
5-amino-2-({1-[19-(butan-2-yl)-16-(2-carbamoylethyl)-13-(carbamoylmethyl)-22-[(4-methoxyphenyl)methyl]-12,15,18,21,24-pentaoxo-7,8-dithia-11,14,17,20,23-pentaazaspiro[5.19]pentacosane-10-carbonyl]pyrrolidin-2-yl}formamido)-N-(carbamoylmethyl)pentanamide
Pyoverdin G4R
3-[(4-Amino-1-{[2-carboxy-2-hydroxy-1-(6-{[({2-hydroxy-1-[(1-hydroxy-2-oxopiperidin-3-yl)-C-hydroxycarbonimidoyl]ethyl}-C-hydroxycarbonimidoyl)methyl]-C-hydroxycarbonimidoyl}-1,4,5,6-tetrahydropyrimidin-2-yl)ethyl]-C-hydroxycarbonimidoyl}butyl)-C-hydroxycarbonimidoyl]-3-[({8,9-dihydroxy-5-[3-(C-hydroxycarbonimidoyl)propanamido]-1H,2H,3H,4H,4ah-pyrimido[1,2-a]quinolin-1-yl}(hydroxy)methylidene)amino]propanoate
URANTIDE
3-Amino-3-{[10-(3-aminopropyl)-16-benzyl-4-[(1-carboxy-2-methylpropyl)-C-hydroxycarbonimidoyl]-6,9,12,15,18-pentahydroxy-7-[(4-hydroxyphenyl)methyl]-13-[(1H-indol-3-yl)methyl]-20,20-dimethyl-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaen-19-yl]-C-hydroxycarbonimidoyl}propanoate
(d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin trifluoroacetate salt
N-[5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[13-(2-amino-2-oxoethyl)-16-(3-amino-3-oxopropyl)-19-butan-2-yl-22-[(4-methoxyphenyl)methyl]-12,15,18,21,24-pentaoxo-7,8-dithia-11,14,17,20,23-pentazaspiro[5.19]pentacosane-10-carbonyl]pyrrolidine-2-carboxamide
4-[[5-amino-1-[[2-carboxy-2-hydroxy-1-[6-[[2-[[3-hydroxy-1-[(1-hydroxy-2-oxopiperidin-3-yl)amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]carbamoyl]-1,4,5,6-tetrahydropyrimidin-2-yl]ethyl]amino]-1-oxopentan-2-yl]amino]-3-[[5-[(4-amino-4-oxobutanoyl)amino]-8,9-dihydroxy-2,3,4,4a-tetrahydro-1H-pyrimido[1,2-a]quinoline-1-carbonyl]amino]-4-oxobutanoic acid
4-[[5-amino-1-[[2-carboxy-2-hydroxy-1-[6-[[2-[[3-hydroxy-1-[(1-hydroxy-2-oxopiperidin-3-yl)amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]carbamoyl]-1,4,5,6-tetrahydropyrimidin-2-yl]ethyl]amino]-1-oxopentan-2-yl]amino]-3-[[5-[(4-amino-4-oxobutanoyl)amino]-8,9-dihydroxy-2,3,4,4a-tetrahydro-1H-pyrimido[1,2-a]quinoline-1-carbonyl]amino]-4-oxobutanoic acid
D064449 - Sequestering Agents > D002614 - Chelating Agents > D007502 - Iron Chelating Agents
BIM-26226
BIM-26226
BIM-26226, gastrin-releasing peptide, is a potent and selective antagonist of bombesin receptor. BIM-26226 inhibits BN- or GRP-stimulated amylase release with IC50s in the nanomolar range. BIM-26226 can be used for the research of cancer[1][2].
16'-[(3,4-dihydroxy-5-{[5-hydroxy-6-(hydroxymethyl)-3,4-bis({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})oxan-2-yl]oxy}-6-(hydroxymethyl)oxan-2-yl)oxy]-7',9',13'-trimethyl-5-methylidene-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-10'-one
16'-[(3,4-dihydroxy-5-{[5-hydroxy-6-(hydroxymethyl)-3,4-bis({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})oxan-2-yl]oxy}-6-(hydroxymethyl)oxan-2-yl)oxy]-7',9',13'-trimethyl-5-methylidene-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-10'-one
(2s,3s,6r,8s)-8-[(2s,3s,6r,9s)-3-{[(2r)-2-hydroxy-2-(3-hydroxy-3-methylbutyl)-4-methoxy-4-oxobutanoyl]oxy}-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.0²,⁶.0⁶,¹⁰.0¹⁵,¹⁹]icosa-1(20),4,13,15(19)-tetraen-9-yl]-4-methoxy-9-oxo-16,18-dioxa-10-azapentacyclo[11.7.0.0²,⁶.0⁶,¹⁰.0¹⁵,¹⁹]icosa-1(20),4,13,15(19)-tetraen-3-yl 1-methyl (3r)-3-hydroxy-3-(3-hydroxy-3-methylbutyl)butanedioate
(2s,3s,6r,8s)-8-[(2s,3s,6r,9s)-3-{[(2r)-2-hydroxy-2-(3-hydroxy-3-methylbutyl)-4-methoxy-4-oxobutanoyl]oxy}-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.0²,⁶.0⁶,¹⁰.0¹⁵,¹⁹]icosa-1(20),4,13,15(19)-tetraen-9-yl]-4-methoxy-9-oxo-16,18-dioxa-10-azapentacyclo[11.7.0.0²,⁶.0⁶,¹⁰.0¹⁵,¹⁹]icosa-1(20),4,13,15(19)-tetraen-3-yl 1-methyl (3r)-3-hydroxy-3-(3-hydroxy-3-methylbutyl)butanedioate
(2e,5r,8s,11r,15s,18s,19s,22r)-2-ethylidene-3,6,9,13,16,20,25-heptahydroxy-8-[2-(4-hydroxyphenyl)ethyl]-15-(1h-indol-3-ylmethyl)-18-[(1e,3e,5s,6s)-6-methoxy-3,5-dimethyl-7-phenylhepta-1,3-dien-1-yl]-5,19-dimethyl-1,4,7,10,14,17,21-heptaazacyclopentacosa-1(25),3,6,9,13,16,20-heptaene-11,22-dicarboxylic acid
(2e,5r,8s,11r,15s,18s,19s,22r)-2-ethylidene-3,6,9,13,16,20,25-heptahydroxy-8-[2-(4-hydroxyphenyl)ethyl]-15-(1h-indol-3-ylmethyl)-18-[(1e,3e,5s,6s)-6-methoxy-3,5-dimethyl-7-phenylhepta-1,3-dien-1-yl]-5,19-dimethyl-1,4,7,10,14,17,21-heptaazacyclopentacosa-1(25),3,6,9,13,16,20-heptaene-11,22-dicarboxylic acid
8-(3-{[2-hydroxy-2-(3-hydroxy-3-methylbutyl)-4-methoxy-4-oxobutanoyl]oxy}-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.0²,⁶.0⁶,¹⁰.0¹⁵,¹⁹]icosa-1(20),4,13,15(19)-tetraen-9-yl)-4-methoxy-9-oxo-16,18-dioxa-10-azapentacyclo[11.7.0.0²,⁶.0⁶,¹⁰.0¹⁵,¹⁹]icosa-1(20),4,13,15(19)-tetraen-3-yl 1-methyl 3-hydroxy-3-(3-hydroxy-3-methylbutyl)butanedioate
8-(3-{[2-hydroxy-2-(3-hydroxy-3-methylbutyl)-4-methoxy-4-oxobutanoyl]oxy}-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.0²,⁶.0⁶,¹⁰.0¹⁵,¹⁹]icosa-1(20),4,13,15(19)-tetraen-9-yl)-4-methoxy-9-oxo-16,18-dioxa-10-azapentacyclo[11.7.0.0²,⁶.0⁶,¹⁰.0¹⁵,¹⁹]icosa-1(20),4,13,15(19)-tetraen-3-yl 1-methyl 3-hydroxy-3-(3-hydroxy-3-methylbutyl)butanedioate
(1'r,2s,2'r,4's,7's,8'r,9's,12'r,13'r,16's)-16'-{[(2r,3r,4r,5r,6r)-3,4-dihydroxy-5-{[(2s,3r,4s,5r,6r)-5-hydroxy-6-(hydroxymethyl)-3,4-bis({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})oxan-2-yl]oxy}-6-(hydroxymethyl)oxan-2-yl]oxy}-7',9',13'-trimethyl-5-methylidene-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-10'-one
(1'r,2s,2'r,4's,7's,8'r,9's,12'r,13'r,16's)-16'-{[(2r,3r,4r,5r,6r)-3,4-dihydroxy-5-{[(2s,3r,4s,5r,6r)-5-hydroxy-6-(hydroxymethyl)-3,4-bis({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})oxan-2-yl]oxy}-6-(hydroxymethyl)oxan-2-yl]oxy}-7',9',13'-trimethyl-5-methylidene-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-18'-en-10'-one
